OCUL Hedge Fund Favor

What happened: Ocular Therapeutix Inc. (OCUL) surged 30% over three consecutive trading sessions, closing at $9.30 on April 14, following positive SOL-1 clinical trial data and anticipation of business updates. On April 13, William Blair maintained an Outperform rating on OCUL, citing the trial's success. OCUL is now among the top 10 biotech stocks with the highest upside potential.

Market impact: The biotech sector, particularly companies focused on ophthalmology, experienced increased investor interest. OCUL's rally pushed its market capitalization past $300 million, attracting more institutional investors. The positive data and analyst support drove a valuation repricing, with OCUL's price-to-sales ratio increasing from 4.5 to 6.5.

What to watch next: OCUL's business updates, scheduled for late April, will provide clarity on the commercialization strategy for its lead drug, DEXTENZA. Additionally, investors await the FDA's decision on OCUL's marketing application for DEXTENZA, expected in Q3 2022. A positive regulatory decision could drive further upside, while any delays or setbacks may lead to a valuation reassessment.